Teva Pharma (TEVA) Tops Q2 EPS by 14c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Teva Reports Second Quarter 2018 Financial Results
August 2, 2018 7:00 AM EDTRevenues of $4.7 billion Free cash flow of $0.6 billion GAAP diluted loss per share of $0.24 Non-GAAP diluted EPS of $0.78 Restructuring plan on-track to achieve $1.5 billion of savings in 2018 and in total $3.0 billion by the end of 2019 Raising 2018 full year guidance: Non-GAAP EPS guidance raised to $2.55-2.80 from $2.40-$2.65 Free cash flow guidance raised to $3.2-3.4 billion from $3.0-3.2 billion
JERUSALEM--(BUSINESS WIRE)--... More
